TY - JOUR
T1 - Viral Infections in HSCT
T2 - Detection, Monitoring, Clinical Management, and Immunologic Implications
AU - Annaloro, Claudio
AU - Serpenti, Fabio
AU - Saporiti, Giorgia
AU - Galassi, Giulia
AU - Cavallaro, Francesca
AU - Grifoni, Federica
AU - Goldaniga, Maria
AU - Baldini, Luca
AU - Onida, Francesco
N1 - Publisher Copyright:
© Copyright © 2021 Annaloro, Serpenti, Saporiti, Galassi, Cavallaro, Grifoni, Goldaniga, Baldini and Onida.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1/20
Y1 - 2021/1/20
N2 - In spite of an increasing array of investigations, the relationships between viral infections and allogeneic hematopoietic stem cell transplantation (HSCT) are still controversial, and almost exclusively regard DNA viruses. Viral infections per se account for a considerable risk of morbidity and mortality among HSCT recipients, and available antiviral agents have proven to be of limited effectiveness. Therefore, an optimal management of viral infection represents a key point in HSCT strategies. On the other hand, viruses bear the potential of shaping immunologic recovery after HSCT, possibly interfering with control of the underlying disease and graft-versus-host disease (GvHD), and eventually with HSCT outcome. Moreover, preliminary data are available about the possible role of some virome components as markers of immunologic recovery after HSCT. Lastly, HSCT may exert an immunotherapeutic effect against some viral infections, notably HIV and HTLV-1, and has been considered as an eradicating approach in these indications.
AB - In spite of an increasing array of investigations, the relationships between viral infections and allogeneic hematopoietic stem cell transplantation (HSCT) are still controversial, and almost exclusively regard DNA viruses. Viral infections per se account for a considerable risk of morbidity and mortality among HSCT recipients, and available antiviral agents have proven to be of limited effectiveness. Therefore, an optimal management of viral infection represents a key point in HSCT strategies. On the other hand, viruses bear the potential of shaping immunologic recovery after HSCT, possibly interfering with control of the underlying disease and graft-versus-host disease (GvHD), and eventually with HSCT outcome. Moreover, preliminary data are available about the possible role of some virome components as markers of immunologic recovery after HSCT. Lastly, HSCT may exert an immunotherapeutic effect against some viral infections, notably HIV and HTLV-1, and has been considered as an eradicating approach in these indications.
KW - adoptive immunotherapy
KW - cytomegalovirus
KW - hematopoietic stem cell transplantation
KW - immunologic recovery
KW - vaccines
KW - viral infection
UR - http://www.scopus.com/inward/record.url?scp=85100523645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100523645&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2020.569381
DO - 10.3389/fimmu.2020.569381
M3 - Review article
C2 - 33552044
AN - SCOPUS:85100523645
VL - 11
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 569381
ER -